Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Sponsor

Changhai Hospital (Other)

Overall Status

Recruiting

CT.gov ID

NCT04146298

Collaborator

(none)

Enrollment

Location

Arm

40.3

Anticipated Duration (Months)

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This clinical trial will evaluate the safety and activity of mutant KRAS G12V-specific TCR transduced T cell therapy for advanced pancreatic cancer patients who express the KRAS G12V mutation and HLA-A*11:01 allele. The theoretical basis of this study is that mutant KRAS antigen-specific TCR transduced autologous Tcells will target and kill HLA-matched mutant KRAS cancer cells but not normal cells.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer Pancreatic Neoplasms Pancreatic Ductal Adenocarcinoma Advanced Cancer	Drug: Cyclophosphamide Drug: Fludarabine Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells Drug: Anti-PD-1 monoclonal antibody	Phase 1/Phase 2

Detailed Description

Hotspot KRAS mutations exist in various cancers, especially pancreatic, lung and colorectal cancer. Mutations in KRAS are implicated in the development of pancreatic cancer and are associated with poor prognosis of the patients. KRAS is an attractive target for cancer treatment because it is a driver mutation and is likely expressed by all cells in a tumor. Recently,T cells targeting mutant KRAS have been identified in patients with epithelial cancers, and these T-cell receptors (TCR) have been characterized. For example, TCRs that target mutant KRAS G12D peptides presented by HLA-C08:02, and a TCR that targets a KRAS G12V peptide presented by HLA-A11:01 have been identified. Mutant KRAS-reactive T cells appear capable of inducing tumor regression as highlighted in a patient with metastatic colorectal cancer who experienced regression of metastatic tumors after infusion of HLA-C08:02-restricted KRAS-G12D reactive tumor-infiltrating lymphocytes (TIL). The investigators will test the safety and activity of adoptive transfer of autologous T cells genetically engineered to express a TCR that targets mutant KRAS G12V in the context of HLA-A11:01 in HLA-matched patients with advanced pancreatic cancer that express mutant KRAS G12V. The investigators will also measure the in vivo survival of engineered T cells.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Clinical Trial Evaluating the Safety and Activity of Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Actual Study Start Date :

Oct 21, 2021

Anticipated Primary Completion Date :

Dec 1, 2024

Anticipated Study Completion Date :

Mar 1, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: TCR Transduced T cell therapy Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9~1e11). If the participant responds to the first infusion, the second or more infusions will be considered when the disease is progressing. Anti-PD-1 therapy: anti-PD-1 will be administered if needed.	Drug: Cyclophosphamide Cyclophosphamide will be administered prior to cell infusion. Drug: Fludarabine Fludarabine will be administered prior to cell infusion. Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes. Drug: Anti-PD-1 monoclonal antibody During the treatment, anti-PD-1 monoclonal antibody will be administered if needed. Other Names: Anti-PD-1

Arm

Intervention/Treatment

Experimental: TCR Transduced T cell therapy

Pre-conditioning: Non-myeloablative, lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine TCR transduced T cell infusion: mutant KRAS G12V-specific TCR transduced autologous T cells (1e9~1e11). If the participant responds to the first infusion, the second or more infusions will be considered when the disease is progressing. Anti-PD-1 therapy: anti-PD-1 will be administered if needed.

Drug: Cyclophosphamide

Cyclophosphamide will be administered prior to cell infusion.

Drug: Fludarabine

Fludarabine will be administered prior to cell infusion.

Biological: Mutant KRAS G12V-specific TCR transduced autologous T cells

After preconditioning regimen, T cells will be infused to the patient intravenously in the Patient Care Unit over approximately 30 to 50 minutes.

Drug: Anti-PD-1 monoclonal antibody

During the treatment, anti-PD-1 monoclonal antibody will be administered if needed.

Other Names:

Anti-PD-1

Outcome Measures

Primary Outcome Measures

Frequency and severity of treatment-related adverse events [18 months following cell infusion]
Aggregate of all adverse events, as well as their frequency and severity
Objective response rate [From the date of cell infusion to disease progression (up to 18 months after cell infusion).]
Percentage of patients who have a clinical response to treatment (objective tumor regression)

Secondary Outcome Measures

The percentage of TCR transduced T cells in peripheral blood [1, 3, 5, 7, 10, 14, 28, 42 and 84 days after cell infusion, then every 3 months, and up to 18 months after cell infusion.]
The percentage of TCR transduced T cells in peripheral blood will be detected with an established flow cytometric assay.
Overall survival [From date of cell infusion until the date of death from any cause, whichever came first, assessed up to 18 months after cell infusion.]
The time between cell infusion and the death of patients

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with measurable and pathologically confirmed advanced pancreatic cancer, including metastatic pancreatic cancer (who have received standard chemotherapy) and recurrent pancreatic cancer (who have received surgery and adjuvant chemotherapy previously).
Patient's tumor must express the KRAS G12V mutation, or a G12V mutation in HRAS or NRAS, as determined by DNA or RNA sequencing methods.
Patients must be HLA-A*11:01.
Patients with brain metastasis may be eligible if they are asymptomatic and there are fewer than 3 brain lesions that are each less than 1 cm in diameter.
Patients between 18 to 75 years old are eligible.
Patients should have good clinical performance status (ECOG 0 or 1).
Patients must practice birth control once enrolled into the study and for up to four months after therapy.
Patients must be seronegative for HIV antibody.
Patients must be seronegative for hepatitis B surface antigen and core antibody (or HBV non-detectable by QPCR).
Patients must be seronegative for hepatitis C antibody (or HCV non-detectable by QPCR).
Baseline hematology criteria:
Absolute neutrophil count of at least 1000/mm^3.
White blood cell count of at least 3000/mm^3.
Platelet count of at least 100,000/mm^3.
Hemoglobin > 8.0 g/dL.
Baseline chemistry criteria:
Serum ALT/AST less than or equal to 3.0 x ULN.
Total bilirubin less than or equal to 1.5 mg/dL, unless the patient has Gilbert's Syndrome in which case total bilirubin must be less than or equal to 3.0 mg/dL.
Serum creatinine less than or equal to 1.6 mg/dL.
Anticipated lifespan greater than 12 weeks.
Patients must be willing and able to comply with all study-related procedures and follow-up requirements.
Patients must be able to understand and sign a written Informed Consent Document as well as a durable power of attorney.

Exclusion Criteria:

Women who are pregnant or breastfeeding.
Patients with any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease or HIV).
Patients with active systemic infections, coagulation disorders, or any other major medical illnesses.
Patients with concurrent opportunistic infections.
Patients on concurrent systemic steroid therapy.
Patients with a history of severe immediate hypersensitivity reaction to any of the medicines used in this study (e.g., cyclophosphamide, fludarabine).
Patients with active coronary ischemic symptoms.
Patients who are receiving any other investigational agents.